TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities researchers at Jefferies Group increased their FY2017 EPS estimates for TG Therapeutics in a research report issued to clients and investors on Thursday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will post earnings per share of ($1.77) for the year, up from their prior estimate of ($1.84). Jefferies Group also issued estimates for TG Therapeutics’ Q4 2017 earnings at ($0.45) EPS, FY2018 earnings at ($1.75) EPS, FY2019 earnings at ($1.71) EPS and FY2020 earnings at ($0.88) EPS.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.05). TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. WARNING: This report was first published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.truebluetribune.com/2017/11/14/fy2017-earnings-estimate-for-tg-therapeutics-inc-issued-by-jefferies-group-tgtx.html.
TGTX has been the topic of a number of other reports. Zacks Investment Research cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. BidaskClub raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. SunTrust Banks, Inc. reissued a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a research report on Tuesday, October 3rd. Finally, ValuEngine cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $25.11.
TG Therapeutics (TGTX) opened at $8.25 on Monday. TG Therapeutics has a 52-week low of $4.10 and a 52-week high of $15.35.
Several institutional investors have recently added to or reduced their stakes in TGTX. Legal & General Group Plc increased its stake in shares of TG Therapeutics by 4.1% during the 1st quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 384 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in shares of TG Therapeutics during the 2nd quarter worth about $156,000. Bank of America Corp DE boosted its holdings in shares of TG Therapeutics by 11.0% during the 1st quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 1,395 shares during the period. HighTower Advisors LLC bought a new stake in shares of TG Therapeutics during the 1st quarter worth about $170,000. Finally, BB&T Securities LLC boosted its holdings in shares of TG Therapeutics by 63.0% during the 2nd quarter. BB&T Securities LLC now owns 16,949 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 6,549 shares during the period. Institutional investors own 49.58% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.